このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)

2026年11月14日 更新者:Rahel Bachem

STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial

This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.

STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.

Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.

This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.

The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.

研究の種類

介入

入学 (推定)

70

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Rahel Bachem, Prof. Dr.
  • 電話番号:+41 58 257 35 26
  • メール:rahel.bachem@ost.ch

研究場所

    • Canton of St. Gallen
      • Sankt Gallen、Canton of St. Gallen、スイス、9001
        • Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
  • Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
  • Sufficient German language proficiency to participate in psychotherapy and complete study assessments
  • Capacity to provide written informed consent

Exclusion Criteria:

  • Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
  • Current prolonged grief disorder meeting ICD-11 diagnostic criteria
  • Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
  • Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
  • Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
  • Acute suicidality requiring immediate crisis intervention
  • Ongoing psychotherapy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:STEP Intervention Group

Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

他の:Waitlist Control Group

Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Adjustment Disorder Symptom Severity at Post-Treatment
時間枠:Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)

Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores.

Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
Depressive Symptom Severity
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

二次結果の測定

結果測定
メジャーの説明
時間枠
Anxiety Symptom Severity
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Perceived Stress
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Subjective Well-Being
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Experiential Avoidance
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Adjustment Disorder Diagnostic Status
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Treatment Credibility and Expectancy
時間枠:Immediately after STEP Session 1

Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement.

Immediately after STEP Session 1
Treatment Acceptability and Feasibility
時間枠:Immediately after completion of the 12-session STEP treatment

Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP.

Immediately after completion of the 12-session STEP treatment
Event-Focused Repetitive Thoughts
時間枠:Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年1月1日

一次修了 (推定)

2029年3月1日

研究の完了 (推定)

2029年5月1日

試験登録日

最初に提出

2026年11月14日

QC基準を満たした最初の提出物

2026年11月14日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月14日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • STEP_PILOTSTUDY
  • PT0041_222855 (その他の助成金/資金番号:Swiss National Science Foundation - SNSF)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.

IPD 共有時間枠

The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.

IPD 共有アクセス基準

The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。